Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test

Mutat Res. 2006 Sep 5;607(2):153-9. doi: 10.1016/j.mrgentox.2006.02.004. Epub 2006 Jul 7.

Abstract

Methylphenidate (MPH) is one of the most frequently prescribed drugs for the treatment of attention deficit hyperactivity disorder (ADHD). A report on cytogenetic effects observed in peripheral lymphocytes from children treated for 3 months with MPH raised questions about the genetic toxicity of this compound. A critical review of this data concluded that the cytogenetic effects in treated children remain unexplained. A literature review showed that MPH was found negative in most genetox studies performed, but no in vitro chromosome aberration data in human lymphocytes have been published. Therefore, we conducted a chromosomal aberration study in cultured human peripheral lymphocytes. The results of this investigation showed that d,l-methylphenidate (MPH, Ritalin) in concentrations up to 10 mM did neither induce structural nor numerical chromosome abnormalities. An oral mouse bone-marrow micronucleus test in B6C3F(1) mice, with doses up to 250 mg/kg bw, was negative too. The data of these studies confirm the absence of clastogenic activity of MPH in non-clinical studies.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Cell Culture Techniques
  • Cells, Cultured
  • Central Nervous System Stimulants / therapeutic use
  • Dose-Response Relationship, Drug
  • Humans
  • Leukocytes, Mononuclear / cytology*
  • Methylphenidate / chemistry
  • Methylphenidate / pharmacology*
  • Methylphenidate / toxicity
  • Mice
  • Mice, Inbred Strains
  • Micronucleus Tests / methods*
  • Models, Chemical
  • Mutagens / pharmacology*
  • Time Factors

Substances

  • Central Nervous System Stimulants
  • Mutagens
  • Methylphenidate